BioNexus Gene Lab appoints Chong Set Fui as CFO effective immediately

BioNexus Gene Lab Corp

Appointed Chong Set Fui (Angeline) as CFO and Principal Financial Officer, effective June 17, 2025.
Chong has 25+ years senior financial experience, most recently CFO of Avillion Berhad (2013-2024).
Monthly salary RM15,000 (~$3,500 USD) plus medical, fuel allowance, and discretionary bonus.
Appointment is for a fixed term from June 17, 2025 to June 16, 2027, renewable with one-month notice.
Su-Leng Tan Lee ceased as acting CFO concurrently.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Su-Leng Tan Lee

acting Chief Financial Officer and Principal Financial Officer

BGLC · BioNexus Gene Lab Corp

Effective: 2025-06-17
Successor: Chong Set Fui (Angeline)
Filed: Jun 23, 2025 23:59 UTC

Concurrent with the new appointment, Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company.

Appointed

Chong Set Fui (Angeline)

Chief Financial Officer and Principal Financial Officer

BGLC · BioNexus Gene Lab Corp

Effective: 2025-06-17
Filed: Jun 23, 2025 23:59 UTC

On June 17, 2025, the Board of Directors of BioNexus Gene Lab Corp. (the “Company”) appointed Ms. Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately.

Source: SEC EDGAR

accession 0001477932-25-004754

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.